Skip to main content
OpenTrials
Completed

NCT Number: NCT02034734

A Study to Investigate the Appearance and Disappearance of ASP3652 in Blood and Spinal Fluid in Healthy Male Subjects

The purpose of this study is to evaluate the plasma and cerebrospinal fluid (CSF) pharmacokinetics (PK) of multiple doses of ASP3652 in healthy young Caucasian male subjects. Also to evaluate the plasma and CSF pharmacodynamics (PD) of multiple doses of ASP3652 in healthy young Caucasian male subjects and to assess the safety and tolerability of multiple doses of ASP3652 in healthy young Caucasian male subjects.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Pharmacokinetics of ASP3652 Healthy Subjects Pharmacodynamics of ASP3652

Age range

18 year–55 year

Sex eligibility

Male

Study type

Interventional

Phase

Phase 1

Primary location

PAREXEL Early Phase Clinical Unit

Harrow, HA1 3UJ, United Kingdom

About this study

Screening takes place between Day -22 to Day -2. Subjects are admitted to the clinical on Day -1 and remain until Day 12.

On Days 5 to 9, subjects receive twice-daily doses of ASP3652, and a single dose on the morning of Day 10. Subjects fast for 10h before the morning dose on Days 5 to 9 and they are served the first standard meal 1h after the morning dose.

A spinal tap is used to collect cerebrospinal fluid (CSF) on Day 1 and Day 10. A plasma sample for PK sample is obtained before first dosing on Day 5. To confirm steady-state concentrations of ASP3652 in plasma, blood samples are obtained before the morning dose on Days 7, 9 and 10, and before the evening dose on Days 5, 7 and 9. On Day 10, a PK profile of ASP3652 in plasma is obtained for up to 48h after the morning dose and for up to 24h in CSF.

Profiles of several enzyme substrates in plasma and seminal fluid (exploratory) are obtained on Day 1 and Day 10 up to 24h in CSF and up to 48h in plasma, before the morning and evening dose on Days 5, 7 and 9 in plasma.

Vital signs, 12-lead electrocardiograms (ECGs), safety laboratory assessments, adverse events (AEs) and concomitant medication are monitored throughout the investigational period until the ESV.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Subject is white and of Caucasian origin.
  • Body Mass Index more than or equal to 18.5 and less than 30.0 kg/m2.
  • Male subject must agree to practice an adequate contraceptive method with female sexual partners to prevent pregnancy.

Exclusion criteria

  • Known or suspected hypersensitivity to ASP3652 or any components of the formulation used.
  • History of excessive bleeding or bruising.
  • Abnormalities of coagulation screen including platelet count, prothrombin time (PT) and activated partial thromboplastin time (aPTT).

Treatment and study plan

ASP3652

Drug

oral

Primary outcomes

  1. Pharmacokinetics (PK) of ASP3652 in plasma measured by area under the plasma concentration-time curve in the dosing interval (AUCtau)

    Time frame: Days 5, 7 and 9, and Days 10 - 12

  2. PK of ASP3652 in plasma measured by maximum observed plasma concentration (Cmax)

    Time frame: Days 5, 7 and 9, and Days 10 - 12

  3. PK parameter of ASP3652 in cerebrospinal fluid (CSF) measured by area under the plasma concentration-time curve in the dosing interval (AUCtau)

    Time frame: Days 10 -11

  4. PK parameter of ASP3652 in cerebrospinal fluid (CSF) measured by maximum observed plasma concentration (Cmax)

    Time frame: Days 10 -11

Secondary outcomes

  1. Additional PK of multiple doses of ASP3652 in plasma and cerebrospinal fluid (CSF)

    Time frame: Plasma: Days 5, 7 and 9, and Days 10 - 12 / CSF: Days 10 -11

    plasma concentration immediately before the next dose (Ctrough), time to attain Cmax (tmax), apparent terminal elimination half-life (t½), volume of terminal phase distribution at steady state (Vz/F), apparent clearance after oral administration at steady state (CL/F) and peak trough ratio (PTR)

  2. Pharmacodynamics (PD) of multiple doses of ASP3652 in plasma and CSF

    Time frame: Plasma: Days 1-3 and Days 5-12 / CSF: Days 1-2 and Days 10-11

    response immediately prior to dosing (Rtrough), time of the maximum response (tmaxR), maximum response (Rmax), area under the response-time curve from 0 to 12h (AURC0-12h), percentage change in maximum response (Rmax%), percentage change in AURC from 0 to 12h (AUR0-12h%)

  3. Safety and tolerability of multiple doses of ASP3652

    Time frame: Screening (Day -22 to Day -2) to End-of-Study Visit (7 to 14 days after (early) discharge)

Sponsors and collaborators

Lead sponsor

Astellas Pharma Europe B.V.

Industry

Registry information

Official study title

A Phase I, Open-label Study to Investigate the Safety, Tolerability and Plasma and Cerebrospinal Fluid Pharmacokinetics and Pharmacodynamics of Multiple Doses of ASP3652 in Healthy Young Caucasian Male Subjects

Important dates

Study start
2012
Primary completion
2012
Study completion
2012
First posted
Jan 13, 2014
Registry last updated
Jan 13, 2014

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.